Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer

Gassner, Eva; Poskaite, Paulina

doi:10.1007/s10353-019-0598-5

Cited by 8 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To overcome the limitations of radiologic response evaluation, several alternative assessment methods have been investigated (83)(84)(85). A recent prospective study suggested that partial regression of tumor contact with vascular structures on pancreatic CT indicates a high likelihood of R0 resection and suitability for surgical exploration (86).…”

Section: Resectability Evaluation In Patients Receiving Neoadjuvant Treatmentmentioning

confidence: 99%

The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

Rhee

Park

2021

Korean J Radiol

View full text Add to dashboard Cite

In pancreatic cancer, imaging plays an essential role in surveillance, diagnosis, resectability evaluation, and treatment response evaluation. Pancreatic cancer surveillance in high-risk individuals has been attempted using endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI). Imaging diagnosis and resectability evaluation are the most important factors influencing treatment decisions, where computed tomography (CT) is the preferred modality. EUS, MRI, and positron emission tomography play a complementary role to CT. Treatment response evaluation is of increasing clinical importance, especially in patients undergoing neoadjuvant therapy. This review aimed to comprehensively review the role of imaging in relation to the current treatment strategy for pancreatic cancer, including surveillance, diagnosis, evaluation of resectability and treatment response, and prediction of prognosis.

show abstract

Section: Resectability Evaluation In Patients Receiving Neoadjuvant Treatmentmentioning

confidence: 99%

The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

Rhee

Park

2021

Korean J Radiol

View full text Add to dashboard Cite

show abstract

“…112 La RM con secuencias de difusión no ha demostrado mejores resultados que los hallazgos mencionados en TCMS. 113 Algunos autores han demostrado el potencial valor del PET TC con FDG para evaluar objetivamente la respuesta a la quimiorradioterapia.…”

Section: • ¿Cómo Se Evalúa La Respuesta Al Tratamiento En Un Paciente Con Acdp Borderline O Inoperable En Protocolo De Rescate Con Quimiounclassified

Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas

Moro¹,

Alle²,

Basso³

et al. 2020

Acta gastroenterol. latinoam.

View full text Add to dashboard Cite

show abstract

“…The majority of patients present with distant metastatic disease at the time of diagnosis and around one third of cases present with locally advanced disease [8]. Due to the increasing availability of diagnostic tools like computed tomography (CT), an increasing number of patients are diagnosed in an early locally advanced stage of disease and therefore qualify for neoadjuvant therapy, which has emerged as a standard treatment in borderline resectable PDAC [6,9]. Although novel therapeutic combinations based on gemcitabine or FOLFIRINOX have shown promising results in all stages of disease, a large number of patients suffer from little to no efficacy based on the development of chemoresistance [10].…”

Section: Original Articlementioning

confidence: 99%

Fibroblast growth factor 8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma

et al. 2020

View full text Add to dashboard Cite

Summary Background Despite distinctive advances in the field of pancreatic cancer therapy over the past few years, patient survival remains poor. Fibroblast growth factors 8 (FGF8) and 18 (FGF18) both play a role in modulating the activity of malignant cells and have been identified as promising biomarkers in a number of cancers. However, no data exist on the expression of FGF8 and FGF18 in pancreatic ductal adenocarcinoma (PDAC). Methods Protein expression levels of FGF8 and FGF18 in postoperative specimens of neoadjuvantly treated and primarily resected patients were investigated using immunohistochemistry. Immunostaining scores were calculated as the products of the staining intensity and the staining rate. Scores exceeding the median score were considered as high expression. Results Specimens from 78 patients with PDAC were available and met the eligibility criteria for analysis of protein expression using immunohistochemistry. 15 (19.2%) patients had received neoadjuvant chemotherapy. High protein levels of FGF8 and FGF18 were detected in 40 (51.8%) and 33 (42.3%) patients, respectively. Kaplan–Meier analysis demonstrated significantly shorter overall survival in patients with high expression of FGF8 (p = 0.04). Multivariable Cox proportional hazard regression models revealed that high expression of FGF8 (Hazard ratio [HR] 0.53, 95% Confidence interval [CI] 0.32–0.89, p = 0.016) was an independent prognostic factor for diminished overall survival in patients with PDAC. By contrast, no statistical significance was found for FGF18 overexpression. In addition, the FGF8 protein level correlated with the factor resection margin (p = 0.042). Conclusion FGF8 is a promising target for new anticancer therapies using FGF inhibitors in pancreatic ductal adenocarcinomas.

show abstract

Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer

Cited by 8 publications

References 44 publications

The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas

Fibroblast growth factor 8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About